Latest news with #Vimta
Business Standard
29-04-2025
- Business
- Business Standard
Vimta Labs rises after strong Q4 performance; board OKs 1:1 bonus share issue
Vimta Labs gained 1.42% to Rs 1035.65 after the company reported 31.2% increase in net profit from continuing operations to Rs 18.32 crore on a 31.4% rise in total income to Rs 96.08 crore in Q4 FY25 as compared with Q4 FY24. EBITDA improved by 31.9% to Rs 34.68 crore in Q4 FY25 from Rs 26.30 crore in Q4 FY24. EBITDA margin was 36.1% in Q4 FY25 as against 36.0% in Q4 FY24. Profit before tax in Q4 FY25 stood at Rs 25.03 crore, up by 39.5% from Rs 17.94 crore recorded in Q4 FY24. Tax outgo for the fourth quarter was Rs 6.71 crore as against Rs 3.98 crore in the same period last year. Vimta Labs has reported 36.8% rise in net profit to Rs 66.75 crore on a 19.1% increase in total income to Rs 348.22 crore in FY25 as compared with FY24. Total debt as of 31 March 2025 stood at Rs. 8.5 crore. Cash and cash equivalents, including bank balance, stood at Rs 32.9 crore as of 31 March 2025. The board of Vimta Labs has granted its approval for increasing the companys borrowing powers up to Rs 300 crore, subject to approval of shareholders at the ensuing annual general meeting. The companys board has approved a dividend of Rs 2 per equity share for the financial year 2024-25. The board has also recommended the issue of bonus shares in the ratio of 1:1, subject to the approval of shareholders in the ensuing AGM. Vimta Labs has announced its strategic expansion into Biologics Contract Research and Development services. "This foray marks a significant milestone in our growth journey, reinforcing our commitment to serve the evolving needs of the biopharmaceutical industry. The new service line will focus on Novel Biologic Entities (NBEs), biosimilars, and peptide-based therapeutics using both microbial and mammalian platforms. Capabilities will include end-to-end development from clone and process development to drug product development and biosimilarity assessment. Development lab is being set up, with requisite manpower by Q3 of FY26, and revenues are expected to commence from FY27, the company stated. Harita Vasireddi, managing director, Vimta Labs, said: "We are pleased to report strong earnings and good growth this year, driven by growth in pharmaceutical services. Our pharma business benefited from increased traction in clinical and analytical services, supported by capacity expansion and deeper client engagements. We are excited to announce our entry into Biologics Contract R&D services, a strategic move that aligns with the future of healthcare and enhances our capabilities across the biopharma value chain. This initiative will enable Vimta to offer end-to-end support for biologics development, reinforcing our position as a trusted partner in high-quality, science-driven innovation." Vimta Labs is a leading contract research and testing organization, providing food, agri, bio/pharmaceutical, medical device, speciality chemical, and electronics companies an integrated scientific, technical, and regulatory expertise to support all stages of product development and manufacturing process. Vimta also provides environmental assessments and testing services.
Business Standard
28-04-2025
- Business
- Business Standard
Board of Vimta Labs approves foray into Biologics Contract Research and Development
At meeting held on 28 April 2025The board of Vimta Labs at its meeting held on 28 April 2025 has approved the company's foray into Biologics Contract Research and Development with an investment of Rs 50 crore. The foray into this new segment will help Vimta to enter into the growing CDMO business of biologics and peptides. Powered by Capital Market - Live News
Business Upturn
28-04-2025
- Business
- Business Upturn
Vimta Labs Q4 FY25 profit rises 31% YoY; announces 1:1 bonus issue and new biologics R&D foray
By News Desk Published on April 28, 2025, 19:19 IST Vimta Labs Limited reported robust financial results for the fourth quarter and financial year ended March 31, 2025, backed by strong growth in its pharmaceutical services business. Financial highlights: Total income for Q4FY25 stood at Rs 960.8 million, up 31.4% year-on-year. EBITDA for the quarter was Rs 346.8 million, with margins steady at 36.1%. Profit after tax (PAT) from continuing operations rose 31.2% YoY to Rs 183.2 million, maintaining a PAT margin of 19.1%. Basic EPS for Q4FY25 was Rs 8.2, compared to Rs 6.3 a year ago. For the full year FY25: Total income was reported at Rs 3,482 million, a 19.1% YoY increase. EBITDA grew 29.1% to Rs 1,262 million with margins improving to 36.2%. FY25 PAT rose sharply by 36.8% YoY to Rs 668 million, with a PAT margin of 19.2%. Basic EPS for the year came in at Rs 30. Strategic developments: The Board of Directors has recommended a 1:1 bonus issue of equity shares and a final dividend of Rs 2 per share for FY25, subject to shareholder approval. Vimta also announced a strategic expansion into Biologics Contract Research and Development (R&D) services. The new business will focus on novel biologic entities (NBEs), biosimilars, and peptide-based therapeutics, targeting full operationalization by Q3 FY26, with revenues expected to start from FY27. Additionally, the company highlighted successful cGMP audit clearance by the European Medicines Agency (EMA) and a GCP audit by the Ministry of Health of Kazakhstan. Vimta's food division was awarded the 'Outstanding Laboratory Performance Award 2024' by CII for the second consecutive year. The company completed the merger of EMTAC Laboratories, further strengthening its service portfolio. Management comment: Ms. Harita Vasireddi, Managing Director, stated, 'Our pharma services growth, capacity expansion, and deepened client engagements have contributed to our strong earnings performance. The new biologics initiative positions Vimta for the next phase of healthcare innovation.' Disclaimer: This article is for informational purposes only. Investors are advised to consult certified financial advisors before making any investment decisions. News desk at
